[go: up one dir, main page]

ES2166577T3 - Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos. - Google Patents

Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos.

Info

Publication number
ES2166577T3
ES2166577T3 ES98108039T ES98108039T ES2166577T3 ES 2166577 T3 ES2166577 T3 ES 2166577T3 ES 98108039 T ES98108039 T ES 98108039T ES 98108039 T ES98108039 T ES 98108039T ES 2166577 T3 ES2166577 T3 ES 2166577T3
Authority
ES
Spain
Prior art keywords
carboxilicos
aminotetrahydroisoquinolin
acids
replaced
profilaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98108039T
Other languages
English (en)
Inventor
Manfred Dr Schudok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2166577T3 publication Critical patent/ES2166577T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

LAS COMPOSICIONES DE FORMULA I SON APTAS PARA LA PRODUCCION DE MEDICAMENTOS DESTINADOS A LA PROFILAXIS Y LA TERAPIA DE ENFERMEDADES EN CUYO DESARROLLO PARTICIPA UNA ACTIVIDAD INTENSIFICADA DE LAS METALOPROTEINASAS QUE DEGRADAN LA MATRIZ.
ES98108039T 1997-05-13 1998-05-02 Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos. Expired - Lifetime ES2166577T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19719817A DE19719817A1 (de) 1997-05-13 1997-05-13 Substituierte 6- und 7-Aminotetrahydroisochinolincarbonsäuren

Publications (1)

Publication Number Publication Date
ES2166577T3 true ES2166577T3 (es) 2002-04-16

Family

ID=7829213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98108039T Expired - Lifetime ES2166577T3 (es) 1997-05-13 1998-05-02 Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos.

Country Status (18)

Country Link
US (1) US5962471A (es)
EP (1) EP0878467B1 (es)
JP (1) JP4384277B2 (es)
KR (1) KR19980086989A (es)
CN (1) CN1199045A (es)
AR (1) AR012684A1 (es)
AT (1) ATE207903T1 (es)
AU (1) AU731079B2 (es)
BR (1) BR9803694A (es)
CA (1) CA2237382A1 (es)
CZ (1) CZ145298A3 (es)
DE (2) DE19719817A1 (es)
DK (1) DK0878467T3 (es)
ES (1) ES2166577T3 (es)
HU (1) HUP9801072A3 (es)
PT (1) PT878467E (es)
RU (1) RU2212405C2 (es)
TR (1) TR199800841A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG116433A1 (en) 1996-10-30 2005-11-28 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof.
FR2795730B1 (fr) * 1999-07-01 2001-08-31 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7521061B2 (en) * 1999-12-31 2009-04-21 Rutgers, The State University Of New Jersey Pharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
JP2003519164A (ja) * 1999-12-31 2003-06-17 ルトガーズ、ザ ステイト ユニバーシティ ポリマーマトリクスに基づく生理活性化合物徐放調節用医薬製剤
ATE330601T1 (de) * 2000-04-07 2006-07-15 Samsung Electronics Co Ltd Sulfonamide als matrix-metalloproteinase inhibitoren
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
AU2002324716A1 (en) * 2001-08-17 2003-03-03 Bristol-Myers Squibb Company Patent Department Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or tnf-$g(a) converting enzyme (tace)
US20020055637A1 (en) * 2001-12-21 2002-05-09 Song Liu Methods for synthesis of amino-tetrahydroisoquinoline-carboxylic acids
US6608193B2 (en) 2001-12-21 2003-08-19 The Procter & Gamble Company Methods for synthesis of amino-tetrahydroisoquinoline ring compounds
US6566524B2 (en) * 2001-12-21 2003-05-20 The Procter & Gamble Co. Methods for synthesis of amino-tetrahydroisoquinoline-sulfonamide hydroxamic acids
BR0313727A (pt) * 2002-08-13 2005-07-12 Warner Lambert Co Derivados de isoquinolina como inibidores de metaloproteinase da matriz
DE10344936A1 (de) * 2003-09-27 2005-04-21 Aventis Pharma Gmbh Bicyclische Iminosäurederivate als Inhibitoren von Matrix-Metalloproteinasen
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
DE102005015040A1 (de) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
JP5098011B2 (ja) * 2006-11-20 2012-12-12 国立大学法人山口大学 創傷治癒促進剤
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU575349A1 (ru) * 1975-12-29 1977-10-05 Донецкий государственный университет Способ получени арилсульфонамидных производных 1,2-дигидрохинолина
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4681889A (en) * 1985-12-02 1987-07-21 Syntex (U.S.A.) Inc. Method for treating cardiovascular disease with calcium channel antagonists
US4613606A (en) * 1985-12-02 1986-09-23 Syntex (U.S.A.) Inc. Tetrahydroisoquinoline derivatives
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (es) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (fr) * 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US5714497A (en) * 1993-02-15 1998-02-03 Sanofi Compounds bearing sulphamoyl and amidino radicals, their preparation process and pharmaceutical compositions containing them
WO1995029892A1 (en) * 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
EP0766665B1 (en) * 1994-06-22 1999-07-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) * 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
JP4638560B2 (ja) * 1995-11-13 2011-02-23 ヘキスト・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 環式および複素環式のＮ−置換α−イミノヒドロキサム酸およびカルボン酸
GB9613547D0 (en) * 1996-06-27 1996-08-28 Pharmacia Spa Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
RU2212405C2 (ru) 2003-09-20
JP4384277B2 (ja) 2009-12-16
EP0878467A1 (de) 1998-11-18
HU9801072D0 (en) 1998-07-28
DE59801919D1 (de) 2001-12-06
DE19719817A1 (de) 1998-11-19
KR19980086989A (ko) 1998-12-05
AR012684A1 (es) 2000-11-08
BR9803694A (pt) 2000-03-21
DK0878467T3 (da) 2002-02-18
HUP9801072A3 (en) 1999-03-29
CZ145298A3 (cs) 1998-12-16
CN1199045A (zh) 1998-11-18
EP0878467B1 (de) 2001-10-31
JPH10316662A (ja) 1998-12-02
AU731079B2 (en) 2001-03-22
TR199800841A3 (tr) 1998-12-21
PT878467E (pt) 2002-04-29
AU6593898A (en) 1998-11-19
US5962471A (en) 1999-10-05
HUP9801072A2 (hu) 1999-02-01
ATE207903T1 (de) 2001-11-15
TR199800841A2 (xx) 1998-12-21
CA2237382A1 (en) 1998-11-13

Similar Documents

Publication Publication Date Title
ES2166577T3 (es) Acidos 6- y 7-aminotetrahidroisoquinolin-carboxilicos sustituidos.
ES2195220T3 (es) Acidos sulfonilaminocarboxilicos.
ES2165640T3 (es) Acidos diaminocarboxilicos sustituidos.
MX9703621A (es) Nuevos derivados aminoacidos con actividad mejorada para la resistencia a drogas multiples.
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
ES2106112T3 (es) Derivados de indano-2-mercaptoacetilamida con una actividad inhibidora de encefalinasa y de ace.
CY1105941T1 (el) ΡΕΤΙΝΟΕΙΔΙΚΟΙ ΑΓΩΝΙΣΤΕΣ ΕΚΛΕΚΤΙΚΟΙ ΩΣ ΠΡΟΣ RARγ ΓΙΑ ΤΗ ΘEPΑΠΕΙΑ ΤΟΥ ΕΜΦΥΣΗΜΑΤΟΣ
AR032293A1 (es) Estuche farmaceutico
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
ES2057124T3 (es) Producto terapeutico para el tratamiento de estados peri- o post-menopausicos.
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
ES2173887T3 (es) Nuevos usos farmaceuticos de las enzimas de krill.
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
ES2192349T3 (es) Derivados alfa-hidroxi, amino y halo de acidos hidroxamicos beta-sulfonilo utilizados como inhibidores de metaloproteinas matriciales.
AR012193A1 (es) Nuevas combinaciones terapeuticas
ES2190082T3 (es) Concentrados estables de vitamina c.
ES2181710T3 (es) Adenovirus recombinantes y su utilizacion en terapia genica para el tratamiento de las patologias oculares.
MX9707636A (es) Ascomicinas.
AR013613A1 (es) MICROESFERAS FARMACÉUTICAS DE ÁCIDO VALPROICO PARA LA ADMINISTRACIoN ORAL, PROCEDIMIENTO PARA PREPARARLAS Y FORMAS FARMACÉUTICAS QUE LAS CONTIENEN
ES2180729T3 (es) Tratamiento terapeutico combinado de las patologias hiperproliferantes.
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
ES2066914T3 (es) Factores a1, a2, a3 y h del antibiotico ge 2270.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 878467

Country of ref document: ES